Connection

Kenneth Tew to Humans

This is a "connection" page, showing publications Kenneth Tew has written about Humans.
Connection Strength

1.279
  1. Reductive stress in cancer. Adv Cancer Res. 2021; 152:383-413.
    View in: PubMed
    Score: 0.029
  2. Development of Telintra as an Inhibitor of Glutathione S-Transferase P. Handb Exp Pharmacol. 2021; 264:71-91.
    View in: PubMed
    Score: 0.028
  3. Oxidative Stress in Cancer. Cancer Cell. 2020 08 10; 38(2):167-197.
    View in: PubMed
    Score: 0.027
  4. Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone. J Pharmacol Exp Ther. 2020 08; 374(2):308-318.
    View in: PubMed
    Score: 0.027
  5. S-Glutathionylated Serine Proteinase Inhibitors as Biomarkers for Radiation Exposure in Prostate Cancer Patients. Sci Rep. 2019 09 24; 9(1):13792.
    View in: PubMed
    Score: 0.026
  6. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019 08 15; 79(16):4072-4085.
    View in: PubMed
    Score: 0.025
  7. Racial disparities, cancer and response to oxidative stress. Adv Cancer Res. 2019; 144:343-383.
    View in: PubMed
    Score: 0.025
  8. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res. 2019; 142:187-207.
    View in: PubMed
    Score: 0.025
  9. An evolving understanding of the S-glutathionylation cycle in pathways of redox regulation. Free Radic Biol Med. 2018 05 20; 120:204-216.
    View in: PubMed
    Score: 0.023
  10. ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target. Biochem Pharmacol. 2018 05; 151:188-200.
    View in: PubMed
    Score: 0.023
  11. Preface. Adv Cancer Res. 2017; 136:xi-xiv.
    View in: PubMed
    Score: 0.021
  12. Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344. J Pharmacol Exp Ther. 2016 08; 358(2):199-208.
    View in: PubMed
    Score: 0.020
  13. Glutathione-Associated Enzymes In Anticancer Drug Resistance. Cancer Res. 2016 Jan 01; 76(1):7-9.
    View in: PubMed
    Score: 0.020
  14. Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta. 2015 Aug; 1850(8):1607-21.
    View in: PubMed
    Score: 0.018
  15. Causes and consequences of cysteine S-glutathionylation. J Biol Chem. 2013 Sep 13; 288(37):26497-504.
    View in: PubMed
    Score: 0.017
  16. Sulfiredoxin redox-sensitive interaction with S100A4 and non-muscle myosin IIA regulates cancer cell motility. Biochemistry. 2012 Oct 02; 51(39):7740-54.
    View in: PubMed
    Score: 0.016
  17. Glutathione-s-transferases as determinants of cell survival and death. Antioxid Redox Signal. 2012 Dec 15; 17(12):1728-37.
    View in: PubMed
    Score: 0.015
  18. S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs. Cancer Res. 2012 May 01; 72(9):2383-93.
    View in: PubMed
    Score: 0.015
  19. NrF2 /Keap1 as gatekeepers of redox homeostasis ? do they prevent or cause cancer? Pigment Cell Melanoma Res. 2011 Dec; 24(6):1078-9.
    View in: PubMed
    Score: 0.015
  20. Drug resistance in cancer. Editorial. Biochem Pharmacol. 2012 Apr 15; 83(8):985-6.
    View in: PubMed
    Score: 0.015
  21. The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med. 2011 Jul 15; 51(2):299-313.
    View in: PubMed
    Score: 0.014
  22. Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification. Drug Metab Rev. 2011 May; 43(2):179-93.
    View in: PubMed
    Score: 0.014
  23. Diazeniumdiolate mediated nitrosative stress alters nitric oxide homeostasis through intracellular calcium and S-glutathionylation of nitric oxide synthetase. PLoS One. 2010 Nov 30; 5(11):e14151.
    View in: PubMed
    Score: 0.014
  24. Redox platforms in cancer drug discovery and development. Curr Opin Chem Biol. 2011 Feb; 15(1):156-61.
    View in: PubMed
    Score: 0.014
  25. The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies. Pharmacol Ther. 2011 Feb; 129(2):172-84.
    View in: PubMed
    Score: 0.014
  26. Redox metabolism and malignancy. Curr Opin Pharmacol. 2010 Aug; 10(4):362-8.
    View in: PubMed
    Score: 0.013
  27. Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response. Cancer Res. 2009 Oct 01; 69(19):7626-34.
    View in: PubMed
    Score: 0.013
  28. Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress. J Biol Chem. 2009 Jan 02; 284(1):436-445.
    View in: PubMed
    Score: 0.012
  29. Pharmacology of a mimetic of glutathione disulfide, NOV-002. Biomed Pharmacother. 2009 Feb; 63(2):75-8.
    View in: PubMed
    Score: 0.012
  30. NOV-002, a mimetic of glutathione disulfide. Expert Opin Investig Drugs. 2008 Jul; 17(7):1075-83.
    View in: PubMed
    Score: 0.012
  31. Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response. Oncogene. 2008 Aug 21; 27(36):4877-87.
    View in: PubMed
    Score: 0.012
  32. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res. 2008 Apr 15; 68(8):2870-7.
    View in: PubMed
    Score: 0.012
  33. ABCA2 as a therapeutic target in cancer and nervous system disorders. Expert Opin Ther Targets. 2008 Apr; 12(4):491-504.
    View in: PubMed
    Score: 0.012
  34. Redox in redux: Emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem Pharmacol. 2007 May 01; 73(9):1257-69.
    View in: PubMed
    Score: 0.010
  35. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res. 2006 Jul 01; 66(13):6800-6.
    View in: PubMed
    Score: 0.010
  36. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene. 2006 Mar 13; 25(11):1639-48.
    View in: PubMed
    Score: 0.010
  37. A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol Pharmacol. 2006 Feb; 69(2):501-8.
    View in: PubMed
    Score: 0.010
  38. Evaluation of lipophilins as determinants of tumor cell response to estramustine. J Pharmacol Exp Ther. 2005 Dec; 315(3):1158-62.
    View in: PubMed
    Score: 0.010
  39. TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs. 2005 Aug; 14(8):1047-54.
    View in: PubMed
    Score: 0.010
  40. Characterization of the ATPase activity of human ATP-binding cassette transporter-2 (ABCA2). In Vivo. 2005 Jul-Aug; 19(4):657-60.
    View in: PubMed
    Score: 0.010
  41. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol. 2005; 401:287-307.
    View in: PubMed
    Score: 0.009
  42. Glutathione and ABC transporters as determinants of sensitivity to oxidative and nitrosative stress. J Nutr. 2004 Nov; 134(11):3205S-3206S.
    View in: PubMed
    Score: 0.009
  43. Human ATP-binding cassette transporter-2 (ABCA2) positively regulates low-density lipoprotein receptor expression and negatively regulates cholesterol esterification in Chinese hamster ovary cells. Biochim Biophys Acta. 2004 Jul 05; 1683(1-3):89-100.
    View in: PubMed
    Score: 0.009
  44. Association of ABCA2 expression with determinants of Alzheimer's disease. FASEB J. 2004 Jul; 18(10):1129-31.
    View in: PubMed
    Score: 0.009
  45. Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim Biophys Acta. 2004 Apr 16; 1678(1):22-32.
    View in: PubMed
    Score: 0.009
  46. Organosulfur compounds from alliaceae in the prevention of human pathologies. Biomed Pharmacother. 2004 Apr; 58(3):183-93.
    View in: PubMed
    Score: 0.009
  47. The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother. 2004 Mar; 58(2):100-10.
    View in: PubMed
    Score: 0.009
  48. Small molecule inhibition of hypoxia inducible factor-1alpha: a viable therapeutic approach? Mol Cancer Ther. 2004 Mar; 3(3):245-6.
    View in: PubMed
    Score: 0.009
  49. Amplified differential gene expression microarray. Methods Mol Biol. 2004; 258:95-106.
    View in: PubMed
    Score: 0.009
  50. Trace elements in human physiology and pathology. Copper. Biomed Pharmacother. 2003 Nov; 57(9):386-98.
    View in: PubMed
    Score: 0.009
  51. Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed Pharmacother. 2003 Nov; 57(9):399-411.
    View in: PubMed
    Score: 0.009
  52. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003 Oct 20; 22(47):7369-75.
    View in: PubMed
    Score: 0.009
  53. Phytosterols in the prevention of human pathologies. Biomed Pharmacother. 2003 Oct; 57(8):321-5.
    View in: PubMed
    Score: 0.008
  54. Sensitivity and fidelity of DNA microarray improved with integration of Amplified Differential Gene Expression (ADGE). BMC Genomics. 2003 Jul 14; 4(1):28.
    View in: PubMed
    Score: 0.008
  55. Resistance to phorbol 12-myristate 13-acetate-induced cell growth arrest in an HL60 cell line chronically exposed to a glutathione S-transferase pi inhibitor. Biochem Pharmacol. 2003 May 15; 65(10):1611-22.
    View in: PubMed
    Score: 0.008
  56. The antioxidant role of selenium and seleno-compounds. Biomed Pharmacother. 2003 May-Jun; 57(3-4):134-44.
    View in: PubMed
    Score: 0.008
  57. Reciprocal regulation of expression of the human adenosine 5'-triphosphate binding cassette, sub-family A, transporter 2 (ABCA2) promoter by the early growth response-1 (EGR-1) and Sp-family transcription factors. Nucleic Acids Res. 2003 Feb 01; 31(3):1097-107.
    View in: PubMed
    Score: 0.008
  58. Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am J Pharmacogenomics. 2003; 3(3):157-72.
    View in: PubMed
    Score: 0.008
  59. Integration of amplified differential gene expression (ADGE) and DNA microarray. IUBMB Life. 2002 Dec; 54(6):335-8.
    View in: PubMed
    Score: 0.008
  60. I. Arginine. Biomed Pharmacother. 2002 Nov; 56(9):439-45.
    View in: PubMed
    Score: 0.008
  61. II. Glutamine and glutamate. Biomed Pharmacother. 2002 Nov; 56(9):446-57.
    View in: PubMed
    Score: 0.008
  62. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther. 2002 Oct; 1(12):1089-95.
    View in: PubMed
    Score: 0.008
  63. Estrogens and environmental estrogens. Biomed Pharmacother. 2002 Feb; 56(1):36-44.
    View in: PubMed
    Score: 0.008
  64. Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. J Clin Invest. 2021 08 16; 131(16).
    View in: PubMed
    Score: 0.007
  65. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther. 2001 Jun; 297(3):1067-73.
    View in: PubMed
    Score: 0.007
  66. Gene expression profiling using a novel method: amplified differential gene expression (ADGE). Nucleic Acids Res. 2001 May 15; 29(10):E46.
    View in: PubMed
    Score: 0.007
  67. Cisplatin chemotherapy and renal function. Adv Cancer Res. 2021; 152:305-327.
    View in: PubMed
    Score: 0.007
  68. Nrf2 inhibition sensitizes breast cancer stem cells to ionizing radiation via suppressing DNA repair. Free Radic Biol Med. 2021 06; 169:238-247.
    View in: PubMed
    Score: 0.007
  69. Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res. 2001 Apr 15; 61(8):3339-47.
    View in: PubMed
    Score: 0.007
  70. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther. 2001 Jan; 296(1):1-6.
    View in: PubMed
    Score: 0.007
  71. Altered redox regulation and S-glutathionylation of BiP contribute to bortezomib resistance in multiple myeloma. Free Radic Biol Med. 2020 11 20; 160:755-767.
    View in: PubMed
    Score: 0.007
  72. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug; 294(2):480-7.
    View in: PubMed
    Score: 0.007
  73. Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol. 2000 Jul; 58(1):167-74.
    View in: PubMed
    Score: 0.007
  74. Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther. 1999 Dec; 291(3):1348-55.
    View in: PubMed
    Score: 0.006
  75. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene. 1999 Nov 15; 240(1):149-55.
    View in: PubMed
    Score: 0.006
  76. Nrf2-modulation by seleno-hormetic agents and its potential for radiation protection. Biofactors. 2020 Mar; 46(2):239-245.
    View in: PubMed
    Score: 0.006
  77. Glutathione conjugate interactions with DNA-dependent protein kinase. J Pharmacol Exp Ther. 1999 Sep; 290(3):1101-6.
    View in: PubMed
    Score: 0.006
  78. Oxidative stress induces senescence in breast cancer stem cells. Biochem Biophys Res Commun. 2019 07 05; 514(4):1204-1209.
    View in: PubMed
    Score: 0.006
  79. A seleno-hormetine protects bone marrow hematopoietic cells against ionizing radiation-induced toxicities. PLoS One. 2019; 14(4):e0205626.
    View in: PubMed
    Score: 0.006
  80. Increased expression of DNA-dependent protein kinase confers resistance to adriamycin. Biochim Biophys Acta. 1998 Jul 23; 1381(2):131-8.
    View in: PubMed
    Score: 0.006
  81. The antioxidant effects of Crassostrea gigas extract (JCOE) in human volunteers. In Vivo. 1998 May-Jun; 12(3):305-9.
    View in: PubMed
    Score: 0.006
  82. Coordinate changes in expression of protective genes in drug-resistant cells. Chem Biol Interact. 1998 Apr 24; 111-112:199-211.
    View in: PubMed
    Score: 0.006
  83. Amplification of the ATP-binding cassette 2 transporter gene is functionally linked with enhanced efflux of estramustine in ovarian carcinoma cells. Cancer Res. 1998 Apr 01; 58(7):1332-7.
    View in: PubMed
    Score: 0.006
  84. Selenocompounds in Cancer Therapy: An Overview. Adv Cancer Res. 2017; 136:259-302.
    View in: PubMed
    Score: 0.006
  85. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer. Cancer Res. 2017 12 01; 77(23):6641-6650.
    View in: PubMed
    Score: 0.006
  86. Interaction of estramustine with tubulin isotypes. Biochemistry. 1997 Jan 28; 36(4):871-8.
    View in: PubMed
    Score: 0.005
  87. Importance of glutathione and associated enzymes in drug response. Oncol Res. 1997; 9(6-7):295-302.
    View in: PubMed
    Score: 0.005
  88. Promoter analysis of a human dihydrodiol dehydrogenase. Biochem Biophys Res Commun. 1996 Nov 12; 228(2):524-9.
    View in: PubMed
    Score: 0.005
  89. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol. 1996 Jul; 50(1):149-59.
    View in: PubMed
    Score: 0.005
  90. Adaptive response to glutathione S-transferase inhibitors. Br J Cancer Suppl. 1996 Jul; 27:S93-8.
    View in: PubMed
    Score: 0.005
  91. Glutathione and related enzymes in multidrug resistance. Eur J Cancer. 1996 Jun; 32A(6):967-78.
    View in: PubMed
    Score: 0.005
  92. Effects of chronic ethacrynic acid exposure on glutathione conjugation and MRP expression in human colon tumor cells. Biochem Biophys Res Commun. 1996 May 06; 222(1):111-5.
    View in: PubMed
    Score: 0.005
  93. Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. Mol Pharm. 2016 06 06; 13(6):2010-25.
    View in: PubMed
    Score: 0.005
  94. Glutathione S-transferase pi modulates NF-?B activation and pro-inflammatory responses in lung epithelial cells. Redox Biol. 2016 08; 8:375-82.
    View in: PubMed
    Score: 0.005
  95. Adverse Outcomes Associated with Cigarette Smoke Radicals Related to Damage to Protein-disulfide Isomerase. J Biol Chem. 2016 Feb 26; 291(9):4763-78.
    View in: PubMed
    Score: 0.005
  96. Increased glutathione expression in cells induced by Crassostera gigas extract (JCOE). Biomed Pharmacother. 1996; 50(3-4):149-53.
    View in: PubMed
    Score: 0.005
  97. Glutathione S-transferases. Cancer Treat Res. 1996; 87:83-122.
    View in: PubMed
    Score: 0.005
  98. Influence of ethacrynic acid on glutathione S-transferase pi transcript and protein half-lives in human colon cancer cells. Biochem Pharmacol. 1995 Oct 12; 50(8):1233-8.
    View in: PubMed
    Score: 0.005
  99. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors. Mol Pharmacol. 1995 Oct; 48(4):639-47.
    View in: PubMed
    Score: 0.005
  100. Glyoxalase I in detoxification: studies using a glyoxalase I transfectant cell line. Biochem J. 1995 Jul 01; 309 ( Pt 1):127-31.
    View in: PubMed
    Score: 0.005
  101. Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins. Cancer. 1995 May 15; 75(10):2597-604.
    View in: PubMed
    Score: 0.005
  102. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol. 1994 Nov; 46(5):866-72.
    View in: PubMed
    Score: 0.005
  103. Reaction kinetics and targeting to cellular glutathione S-transferase of the glutathione peroxidase mimetic PhSeZnCl and its D,L-polylactide microparticle formulation. Free Radic Biol Med. 2015 Jan; 78:56-65.
    View in: PubMed
    Score: 0.005
  104. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994 Aug 15; 54(16):4313-20.
    View in: PubMed
    Score: 0.005
  105. cDNA and deduced amino acid sequences of a human colon dihydrodiol dehydrogenase. Biochim Biophys Acta. 1994 Jun 28; 1186(1-2):129-32.
    View in: PubMed
    Score: 0.004
  106. Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. J Biol Chem. 1994 Jun 03; 269(22):15558-62.
    View in: PubMed
    Score: 0.004
  107. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst. 1994 May 04; 86(9):688-94.
    View in: PubMed
    Score: 0.004
  108. Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome. Free Radic Biol Med. 2014 Jul; 72:210-21.
    View in: PubMed
    Score: 0.004
  109. Pleiotropic functions of glutathione S-transferase P. Adv Cancer Res. 2014; 122:143-75.
    View in: PubMed
    Score: 0.004
  110. Analysis of glyoxalase-I from normal and tumor tissue from human colon. Biochim Biophys Acta. 1993 Oct 20; 1182(3):311-6.
    View in: PubMed
    Score: 0.004
  111. Overproduction of a 37.5-kDa cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid-resistant human colon cells. Mol Pharmacol. 1993 Jun; 43(6):845-53.
    View in: PubMed
    Score: 0.004
  112. Cloning and characterization of human colon glyoxalase-I. J Biol Chem. 1993 Mar 15; 268(8):5661-7.
    View in: PubMed
    Score: 0.004
  113. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther. 1992 Dec; 56(3):323-39.
    View in: PubMed
    Score: 0.004
  114. Allelic variants of glutathione S-transferase P1-1 differentially mediate the peroxidase function of peroxiredoxin VI and alter membrane lipid peroxidation. Free Radic Biol Med. 2013 Jan; 54:62-70.
    View in: PubMed
    Score: 0.004
  115. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992 Aug 15; 52(16):4433-40.
    View in: PubMed
    Score: 0.004
  116. Developmental expression of orphan G protein-coupled receptor 50 in the mouse brain. ACS Chem Neurosci. 2012 Jun 20; 3(6):459-72.
    View in: PubMed
    Score: 0.004
  117. Heterogeneity of glutathione S-transferase enzyme and gene expression in ovarian carcinoma. Pharmacogenetics. 1992 Apr; 2(2):63-72.
    View in: PubMed
    Score: 0.004
  118. Increased levels of glutathione S-transferase pi transcript as a mechanism of resistance to ethacrynic acid. Biochem J. 1992 Jan 01; 281 ( Pt 1):219-24.
    View in: PubMed
    Score: 0.004
  119. Immunohistochemical localization of glutathione S-transferases alpha, mu, and pi in normal tissue and carcinomas from human colon. Carcinogenesis. 1991 Dec; 12(12):2383-7.
    View in: PubMed
    Score: 0.004
  120. Down-regulation of the ATP-binding cassette transporter 2 (Abca2) reduces amyloid-? production by altering Nicastrin maturation and intracellular localization. J Biol Chem. 2012 Jan 06; 287(2):1100-11.
    View in: PubMed
    Score: 0.004
  121. Contribution of patient history to the glutathione S-transferase activity of human lung, breast and colon tissue. Carcinogenesis. 1991 Oct; 12(10):1957-61.
    View in: PubMed
    Score: 0.004
  122. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. Br J Cancer. 1991 Aug; 64(2):267-73.
    View in: PubMed
    Score: 0.004
  123. Evidence for a glycoconjugate form of glutathione S-transferase pI. Int J Pept Protein Res. 1991 Jun; 37(6):565-71.
    View in: PubMed
    Score: 0.004
  124. S-glutathionylation: from molecular mechanisms to health outcomes. Antioxid Redox Signal. 2011 Jul 01; 15(1):233-70.
    View in: PubMed
    Score: 0.004
  125. Glutathione S-transferases in normal and malignant human colon tissue. Biochim Biophys Acta. 1991 Apr 15; 1096(3):209-16.
    View in: PubMed
    Score: 0.004
  126. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol. 1991 Apr; 54(2):268-76.
    View in: PubMed
    Score: 0.004
  127. Detoxification mechanisms and tumor cell resistance to anticancer drugs. Med Res Rev. 1991 Mar; 11(2):185-217.
    View in: PubMed
    Score: 0.004
  128. Mechanism based chemotherapy for prostate cancer. Cancer Surv. 1991; 11:239-54.
    View in: PubMed
    Score: 0.004
  129. Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res. 1990 Jun 15; 50(12):3562-8.
    View in: PubMed
    Score: 0.003
  130. Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO. Invest New Drugs. 2011 Oct; 29(5):719-29.
    View in: PubMed
    Score: 0.003
  131. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem. 1990 Mar 15; 265(8):4296-301.
    View in: PubMed
    Score: 0.003
  132. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036. Anticancer Res. 1989 Nov-Dec; 9(6):1617-22.
    View in: PubMed
    Score: 0.003
  133. Intracellular effects of estramustine (Estracyt/Emcyt). Prog Clin Biol Res. 1989; 303:169-75.
    View in: PubMed
    Score: 0.003
  134. Estramustine--a nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther. 1989; 43(3):299-319.
    View in: PubMed
    Score: 0.003
  135. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res. 1988 Jul 01; 48(13):3622-5.
    View in: PubMed
    Score: 0.003
  136. Glutathione S-transferases in human prostate. Biochim Biophys Acta. 1987 Oct 08; 926(1):8-15.
    View in: PubMed
    Score: 0.003
  137. The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking. Biomed Pharmacother. 2006 Nov; 60(9):587-92.
    View in: PubMed
    Score: 0.003
  138. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine. Cancer Treat Rep. 1986 Jun; 70(6):715-20.
    View in: PubMed
    Score: 0.003
  139. PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem. 2006 Feb 09; 49(3):1157-64.
    View in: PubMed
    Score: 0.002
  140. Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8483-7.
    View in: PubMed
    Score: 0.002
  141. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 1985 Aug; 45(8):3891-7.
    View in: PubMed
    Score: 0.002
  142. Biochemical and cytotoxic properties of the isomeric forms of N,N'-bis[N-2-chloroethyl)-N-nitrosocarbamoyl] cystamine. Biochem Pharmacol. 1984 Aug 15; 33(16):2575-80.
    View in: PubMed
    Score: 0.002
  143. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer. 2004 Jun 14; 90(12):2411-7.
    View in: PubMed
    Score: 0.002
  144. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology. 1984 Jun; 23(6 Suppl):28-33.
    View in: PubMed
    Score: 0.002
  145. Sulfur containing amino acids and human disease. Biomed Pharmacother. 2004 Jan; 58(1):47-55.
    View in: PubMed
    Score: 0.002
  146. Alkylating agent interactions with the nuclear matrix. Biochem Pharmacol. 1983 Dec 01; 32(23):3509-16.
    View in: PubMed
    Score: 0.002
  147. The mechanism of action of estramustine. Semin Oncol. 1983 Sep; 10(3 Suppl 3):21-6.
    View in: PubMed
    Score: 0.002
  148. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. Mol Pharmacol. 1983 Sep; 24(2):324-8.
    View in: PubMed
    Score: 0.002
  149. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003 Aug; 64(2):382-94.
    View in: PubMed
    Score: 0.002
  150. The importance of glutathione in human disease. Biomed Pharmacother. 2003 May-Jun; 57(3-4):145-55.
    View in: PubMed
    Score: 0.002
  151. Polyphenols: do they play a role in the prevention of human pathologies? Biomed Pharmacother. 2002 Jun; 56(4):200-7.
    View in: PubMed
    Score: 0.002
  152. Enhancement of nitrosourea cytotoxicity in vitro using hydrocortisone. Biochem Pharmacol. 1982 Mar 15; 31(6):1179-80.
    View in: PubMed
    Score: 0.002
  153. Influence of hydrocortisone on the binding of nitrosoureas to nuclear chromatin subfractions. Cancer Res. 1980 Oct; 40(10):3697-3703.
    View in: PubMed
    Score: 0.002
  154. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46.
    View in: PubMed
    Score: 0.002
  155. Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 1999 Nov 01; 18(45):6104-11.
    View in: PubMed
    Score: 0.002
  156. Oxidative stress induced in pathologies: the role of antioxidants. Biomed Pharmacother. 1999 May; 53(4):169-80.
    View in: PubMed
    Score: 0.002
  157. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. Int J Cancer. 1998 Aug 12; 77(4):626-31.
    View in: PubMed
    Score: 0.001
  158. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res. 1998 Jun 15; 58(12):2568-75.
    View in: PubMed
    Score: 0.001
  159. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol. 1998 Feb 01; 55(3):325-31.
    View in: PubMed
    Score: 0.001
  160. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun 01; 56(11):2584-9.
    View in: PubMed
    Score: 0.001
  161. Cellular and in vitro transport of glutathione conjugates by MRP. Biochemistry. 1996 May 07; 35(18):5719-25.
    View in: PubMed
    Score: 0.001
  162. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol. 1996; 37(4):363-70.
    View in: PubMed
    Score: 0.001
  163. Glutathione and drug resistance. Cancer Invest. 1996; 14(2):158-68.
    View in: PubMed
    Score: 0.001
  164. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol Oncol Clin North Am. 1995 Apr; 9(2):383-96.
    View in: PubMed
    Score: 0.001
  165. Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther. 1994 Sep; 270(3):1186-91.
    View in: PubMed
    Score: 0.001
  166. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992 Nov; 10(11):1754-61.
    View in: PubMed
    Score: 0.001
  167. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst. 1992 Feb 19; 84(4):264-7.
    View in: PubMed
    Score: 0.001
  168. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991 Nov 15; 51(22):6059-65.
    View in: PubMed
    Score: 0.001
  169. Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid. Biochem Pharmacol. 1991 Sep 12; 42(7):1504-7.
    View in: PubMed
    Score: 0.001
  170. Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry. 1991 Aug 27; 30(34):8371-9.
    View in: PubMed
    Score: 0.001
  171. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J Cancer Res. 1990 May; 81(5):527-35.
    View in: PubMed
    Score: 0.001
  172. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol. 1988 Dec; 107(6 Pt 2):2647-56.
    View in: PubMed
    Score: 0.001
  173. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine. Anticancer Res. 1987 Nov-Dec; 7(6):1165-71.
    View in: PubMed
    Score: 0.001
  174. Mechanism of action of 2-haloethylnitrosoureas on deoxyribonucleic acid. Pathways of aqueous decomposition and pharmacological characteristics of new anticancer disulfide-linked nitrosoureas. Biochem Pharmacol. 1985 Apr 01; 34(7):1015-24.
    View in: PubMed
    Score: 0.001
  175. Effect of 1-methyl-1-nitrosourea on poly(adenosine diphosphate-ribose) polymerase activity at the nucleosomal level. Cancer Res. 1979 Apr; 39(4):1405-10.
    View in: PubMed
    Score: 0.000
  176. Nitrosourea interaction with chromatin and effect on poly(adenosine diphosphate ribose) polymerase activity. Cancer Res. 1979 Apr; 39(4):1411-7.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.